Conclusions
Tumors, fracture, Prostate Cancer
BONE LESIONS, DISEASE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, CASTRATION-RESISTANT PROSTATE CANCER, PROSTATE CANCER, TUMORS, EVENTS, METASTASES, BONE METASTASES
DWI is useful for assessment of disease response in bone. Response to radium-223 is heterogeneous, both between patients and between different metastases in the same patient. New bone metastases appear during radium-223 treatment.The REASURE trial is registered under ISRCTN17805587.Radium-223 is a bone-seeking, ɑ-emitting radionuclide that is approved for use in metastatic castration-resistant prostate cancer. The ALSYMPCA trial showed that radium-223 improves overall survival, quality of life, and time to skeletal events (Radium-223 is used for men with bone metastases from castration-resistant prostate cancer. Assessment of disease response in bone metastases is suboptimal; sclerotic bone lesions cannot be evaluated on computed tomography/Response Evaluation Criteria in Solid Tumors, and standard imaging criteria from the Prostate Cancer Working Group define progression based only on development of new bone lesions, confirmed on a subsequent scan (Whole-body diffusion-weighted magnetic resonance imaging (DWI), combining standard anatomical sequences with a functional sequence, has emerged as a new imaging method able to document response and progression in bone metastases (We conducted a prospective phase 2 study of radium-223 incorporating whole-body DWI in men with metastatic castration-resistant prostate cancer. We have previously reported on treatment compliance and on fracture risk after treatment (